Shanghai Junshi Biosciences Co Ret. on assets
What is the Ret. on assets of Shanghai Junshi Biosciences Co?
The Ret. on assets of Shanghai Junshi Biosciences Co., Ltd. is -18.56%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Health Care sector on OTC compared to Shanghai Junshi Biosciences Co
What does Shanghai Junshi Biosciences Co do?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Companies with ret. on assets similar to Shanghai Junshi Biosciences Co
- Universe Printshop has Ret. on assets of -18.59%
- Novacyt S.A has Ret. on assets of -18.59%
- Novacyt S.A has Ret. on assets of -18.59%
- Leigh Creek has Ret. on assets of -18.58%
- Bigblu Broadband plc has Ret. on assets of -18.57%
- Wayfair Inc has Ret. on assets of -18.56%
- Shanghai Junshi Biosciences Co has Ret. on assets of -18.56%
- ChemoCentryx Inc has Ret. on assets of -18.55%
- Western Asset High Income Opportunity Fund Inc has Ret. on assets of -18.55%
- Cairn Plc has Ret. on assets of -18.55%
- Cairn PLC has Ret. on assets of -18.55%
- Lifecore Biomedical Inc has Ret. on assets of -18.54%
- Netgear Inc has Ret. on assets of -18.53%